• PDF: Delivered by email usually within 4 to 8 UK business hours.
  • PRINT/CD-ROM: Despatched within 1 to 2 working days.

OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide

  • Publication Date:November 2010
  • Publisher:Datamonitor
  • Product Type: Report
  • Pages:215

OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide

Datamonitor's OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry in Brazil, Hungary, Mexico, Poland, South Africa, and Taiwan. The report includes easily comparable data on market value, volume, segmentation and market share for the advanced emerging markets otc pharmaceuticals markets, plus full five-year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

  • Contains an executive summary and data on value, volume and segmentation
  • Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
  • Incorporates in-depth five forces competitive environment analysis and scorecards
  • Compares data from Brazil, Hungary, Mexico, Poland, South Africa and Taiwan, alongside individual chapters on each country. .
  • Includes a five-year forecast of the industry

Highlights

The advanced emerging market countries contributed $8,059.5 million to the global otc pharmaceuticals industry in 2005, with a compound annual growth rate (CAGR) of 6.5% between 2005 and 2009 bringing this contribution to $10,370.4million.

These countries are expected to reach a value of $13,331.5 million in 2014, with a CAGR of 5.2% over the 2009-14 period.

Brazil holds the major share of the OTC pharmaceutical industry. In 2009, it accounted for 36.1% of the market.

Why you should buy this report

  • Spot future trends and developments
  • Inform your business decisions
  • Add weight to presentations and marketing materials
  • Save time carrying out entry-level research

Market Definition

The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria's, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness).

  • Table Of Contents
  • Introduction
    • What Is This Report About?
    • Who Is The Target Reader?
    • Definition
  • Advanced Emerging Markets Otc Pharmaceuticals Industry Outlook
  • Otc Pharmaceuticals In Brazil
    • Market Overview
    • Market Value
    • Market Segmentation I
    • Market Segmentation Ii
    • Market Share
    • Five Forces Analysis
    • Leading Companies
    • Market Distribution
    • Market Forecasts
    • Macroeconomic Indicators
  • Otc Pharmaceuticals In Hungary
    • Market Overview
    • Market Value
    • Market Segmentation I
    • Market Segmentation Ii
    • Market Share
    • Five Forces Analysis
    • Leading Companies
    • Market Distribution
    • Market Forecasts
    • Macroeconomic Indicators
  • Otc Pharmaceuticals In Mexico
    • Market Overview
    • Market Value
    • Market Segmentation I
    • Market Segmentation Ii
    • Market Share
    • Five Forces Analysis
    • Leading Companies
    • Market Distribution
    • Market Forecasts
    • Macroeconomic Indicators
  • Otc Pharmaceuticals In Poland
    • Market Overview
    • Market Value
    • Market Segmentation I
    • Market Segmentation Ii
    • Market Share
    • Five Forces Analysis
    • Leading Companies
    • Market Distribution
    • Market Forecasts
    • Macroeconomic Indicators
  • Otc Pharmaceuticals In South Africa
    • Market Overview
    • Market Value
    • Market Segmentation I
    • Market Share
    • Five Forces Analysis
    • Leading Companies
    • Market Distribution
    • Market Forecasts
    • Macroeconomic Indicators
  • Otc Pharmaceuticals In Taiwan
    • Market Overview
    • Market Value
    • Market Segmentation I
    • Market Segmentation Ii
    • Market Share
    • Five Forces Analysis
    • Leading Companies
    • Market Distribution
    • Market Forecasts
    • Macroeconomic Indicators
  • Appendix
    • Data Research Methodology
    • About Datamonitor
    • Disclaimer
  • List Of Tables
    • Table 1: Advanced emerging markets otc pharmaceuticals industry, revenue ($m), 2005-14
    • Table 2: Advanced emerging markets otc pharmaceuticals industry, revenue by country ($m), 2005-09
    • Table 3: Advanced emerging markets otc pharmaceuticals industry forecast, revenue by country ($m), 2009-14
    • Table 4: Brazil OTC pharmaceuticals market value: $ million, 2005-09
    • Table 5: Brazil OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 6: Brazil OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Table 7: Brazil OTC pharmaceuticals market share: % share, by value, 2009
    • Table 8: Johnson & Johnson: key facts
    • Table 9: Johnson & Johnson: key financials ($)
    • Table 10: Johnson & Johnson: key financial ratios
    • Table 11: Sanofi-Aventis: key facts
    • Table 12: Sanofi-Aventis: key financials ($)
    • Table 13: Sanofi-Aventis: key financials (€)
    • Table 14: Sanofi-Aventis: key financial ratios
    • Table 15: Abbott Laboratories: key facts
    • Table 16: Abbott Laboratories: key financials ($)
    • Table 17: Abbott Laboratories: key financial ratios
    • Table 18: Brazil OTC pharmaceuticals market distribution: % share, by value, 2009
    • Table 19: Brazil OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 20: Brazil size of population (million), 2005-09
    • Table 21: Brazil gdp (constant 2000 prices, $ billion), 2005-09
    • Table 22: Brazil gdp (current prices, $ billion), 2005-09
    • Table 23: Brazil inflation, 2005-09
    • Table 24: Brazil consumer price index (absolute), 2005-09
    • Table 25: Brazil exchange rate, 2005-09
    • Table 26: Hungary OTC pharmaceuticals market value: $ million, 2005-09
    • Table 27: Hungary OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 28: Hungary OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Table 29: Hungary OTC pharmaceuticals market share: % share, by value, 2009
    • Table 30: Johnson & Johnson: key facts
    • Table 31: Johnson & Johnson: key financials ($)
    • Table 32: Johnson & Johnson: key financial ratios
    • Table 33: Béres Pharmaceuticals Co. Ltd: key facts
    • Table 34: EGIS Pharmaceuticals Ltd.: key facts
    • Table 35: EGIS Pharmaceuticals Ltd.: key financials ($)
    • Table 36: EGIS Pharmaceuticals Ltd.: key financials (HUF)
    • Table 37: EGIS Pharmaceuticals Ltd.: key financial ratios
    • Table 38: Hungary OTC pharmaceuticals market distribution: % share, by value, 2009
    • Table 39: Hungary OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 40: Hungary size of population (million), 2005-09
    • Table 41: Hungary gdp (constant 2000 prices, $ billion), 2005-09
    • Table 42: Hungary gdp (current prices, $ billion), 2005-09
    • Table 43: Hungary inflation, 2005-09
    • Table 44: Hungary consumer price index (absolute), 2005-09
    • Table 45: Hungary exchange rate, 2005-09
    • Table 46: Mexico OTC pharmaceuticals market value: $ million, 2005-09
    • Table 47: Mexico OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 48: Mexico OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Table 49: Mexico OTC pharmaceuticals market share: % share, by value, 2009
    • Table 50: Bayer AG: key facts
    • Table 51: Bayer AG: key financials ($)
    • Table 52: Bayer AG: key financials (€)
    • Table 53: Bayer AG: key financial ratios
    • Table 54: Johnson & Johnson: key facts
    • Table 55: Johnson & Johnson: key financials ($)
    • Table 56: Johnson & Johnson: key financial ratios
    • Table 57: Boehringer Ingelheim GmbH: key facts
    • Table 58: Boehringer Ingelheim GmbH: key financials ($)
    • Table 59: Boehringer Ingelheim GmbH: key financials (€)
    • Table 60: Boehringer Ingelheim GmbH: key financial ratios
    • Table 61: Mexico OTC pharmaceuticals market distribution: % share, by value, 2009
    • Table 62: Mexico OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 63: Mexico size of population (million), 2005-09
    • Table 64: Mexico gdp (constant 2000 prices, $ billion), 2005-09
    • Table 65: Mexico gdp (current prices, $ billion), 2005-09
    • Table 66: Mexico inflation, 2005-09
    • Table 67: Mexico consumer price index (absolute), 2005-09
    • Table 68: Mexico exchange rate, 2005-09
    • Table 69: Poland OTC pharmaceuticals market value: $ million, 2005-09
    • Table 70: Poland OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 71: Poland OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Table 72: Poland OTC pharmaceuticals market share: % share, by value, 2009
    • Table 73: GlaxoSmithKline Plc: key facts
    • Table 74: GlaxoSmithKline Plc: key financials ($)
    • Table 75: GlaxoSmithKline Plc: key financials (£)
    • Table 76: GlaxoSmithKline Plc: key financial ratios
    • Table 77: US Pharmacia: key facts
    • Table 78: Herbapol Wroclaw SA: key facts
    • Table 79: Poland OTC pharmaceuticals market distribution: % share, by value, 2009
    • Table 80: Poland OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 81: Poland size of population (million), 2005-09
    • Table 82: Poland gdp (constant 2000 prices, $ billion), 2005-09
    • Table 83: Poland gdp (current prices, $ billion), 2005-09
    • Table 84: Poland inflation, 2005-09
    • Table 85: Poland consumer price index (absolute), 2005-09
    • Table 86: Poland exchange rate, 2005-09
    • Table 87: South Africa OTC pharmaceuticals market value: $ million, 2005-09
    • Table 88: South Africa OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 89: South Africa OTC pharmaceuticals market share: % share, by value, 2009
    • Table 90: Pharma Natura (Pty) Ltd: key facts
    • Table 91: Weleda Group: key facts
    • Table 92: Johnson & Johnson: key facts
    • Table 93: Johnson & Johnson: key financials ($)
    • Table 94: Johnson & Johnson: key financial ratios
    • Table 95: South Africa OTC pharmaceuticals market distribution: % share, by value, 2009
    • Table 96: South Africa OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 97: South Africa size of population (million), 2005-09
    • Table 98: South Africa gdp (constant 2000 prices, $ billion), 2005-09
    • Table 99: South Africa gdp (current prices, $ billion), 2005-09
    • Table 100: South Africa inflation, 2005-09
    • Table 101: South Africa consumer price index (absolute), 2005-09
    • Table 102: South Africa exchange rate, 2005-09
    • Table 103: Taiwan OTC pharmaceuticals market value: $ million, 2005-09
    • Table 104: Taiwan OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 105: Taiwan OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Table 106: Taiwan OTC pharmaceuticals market share: % share, by value, 2009
    • Table 107: China Chemical and Pharmaceutical Co., Ltd.: key facts
    • Table 108: China Chemical and Pharmaceutical Co., Ltd.: key financials ($)
    • Table 109: China Chemical and Pharmaceutical Co., Ltd.: key financials (NT$)
    • Table 110: China Chemical and Pharmaceutical Co., Ltd.: key financial ratios
    • Table 111: Sinphar pharmaceuticals co ltd: key facts
    • Table 112: Sinphar pharmaceuticals co ltd: key financials ($)
    • Table 113: Sinphar pharmaceuticals co ltd: key financials (NT$)
    • Table 114: Sinphar pharmaceuticals co ltd: key financial ratios
    • Table 115: Daiichi Sankyo, Ltd.: key facts
    • Table 116: Daiichi Sankyo, Ltd.: key financials ($)
    • Table 117: Daiichi Sankyo, Ltd.: key financials (¥)
    • Table 118: Daiichi Sankyo, Ltd.: key financial ratios
    • Table 119: Taiwan OTC pharmaceuticals market distribution: % share, by value, 2009
    • Table 120: Taiwan OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 121: Taiwan size of population (million), 2005-09
    • Table 122: Taiwan gdp (constant 2000 prices, $ billion), 2005-09
    • Table 123: Taiwan gdp (current prices, $ billion), 2005-09
    • Table 124: Taiwan inflation, 2005-09
    • Table 125: Taiwan consumer price index (absolute), 2005-09
    • Table 126: Taiwan exchange rate, 2005-09
  • List Of Figures
    • Figure 1: Advanced emerging markets otc pharmaceuticals industry, revenue ($m), 2005-14
    • Figure 2: Advanced emerging markets otc pharmaceuticals industry, country analysis (%), 2005-14
    • Figure 3: Advanced emerging markets otc pharmaceuticals industry, revenue by country ($m), 2005-09
    • Figure 4: Advanced emerging markets otc pharmaceuticals industry forecast, revenue by country ($m), 2009-14
    • Figure 5: Brazil OTC pharmaceuticals market value: $ million, 2005-09
    • Figure 6: Brazil OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 7: Brazil OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Figure 8: Brazil OTC pharmaceuticals market share: % share, by value, 2009
    • Figure 9: Forces driving competition in the OTC pharmaceuticals market in Brazil, 2009
    • Figure 10: Drivers of buyer power in the OTC pharmaceuticals market in Brazil, 2009
    • Figure 11: Drivers of supplier power in the OTC pharmaceuticals market in Brazil, 2009
    • Figure 12: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Brazil, 2009
    • Figure 13: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Brazil, 2009
    • Figure 14: Drivers of degree of rivalry in the OTC pharmaceuticals market in Brazil, 2009
    • Figure 15: Johnson & Johnson: revenues & profitability
    • Figure 16: Johnson & Johnson: assets & liabilities
    • Figure 17: Sanofi-Aventis: revenues & profitability
    • Figure 18: Sanofi-Aventis: assets & liabilities
    • Figure 19: Abbott Laboratories: revenues & profitability
    • Figure 20: Abbott Laboratories: assets & liabilities
    • Figure 21: Brazil OTC pharmaceuticals market distribution: % share, by value, 2009
    • Figure 22: Brazil OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Figure 23: Hungary OTC pharmaceuticals market value: $ million, 2005-09
    • Figure 24: Hungary OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 25: Hungary OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Figure 26: Hungary OTC pharmaceuticals market share: % share, by value, 2009
    • Figure 27: Forces driving competition in the OTC pharmaceuticals market in Hungary, 2009
    • Figure 28: Drivers of buyer power in the OTC pharmaceuticals market in Hungary, 2009
    • Figure 29: Drivers of supplier power in the OTC pharmaceuticals market in Hungary, 2009
    • Figure 30: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Hungary, 2009
    • Figure 31: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Hungary, 2009
    • Figure 32: Drivers of degree of rivalry in the OTC pharmaceuticals market in Hungary, 2009
    • Figure 33: Johnson & Johnson: revenues & profitability
    • Figure 34: Johnson & Johnson: assets & liabilities
    • Figure 35: EGIS Pharmaceuticals Ltd.: revenues & profitability
    • Figure 36: EGIS Pharmaceuticals Ltd.: assets & liabilities
    • Figure 37: Hungary OTC pharmaceuticals market distribution: % share, by value, 2009
    • Figure 38: Hungary OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Figure 39: Mexico OTC pharmaceuticals market value: $ million, 2005-09
    • Figure 40: Mexico OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 41: Mexico OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Figure 42: Mexico OTC pharmaceuticals market share: % share, by value, 2009
    • Figure 43: Forces driving competition in the OTC pharmaceuticals market in Mexico, 2009
    • Figure 44: Drivers of buyer power in the OTC pharmaceuticals market in Mexico, 2009
    • Figure 45: Drivers of supplier power in the OTC pharmaceuticals market in Mexico, 2009
    • Figure 46: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Mexico, 2009
    • Figure 47: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Mexico, 2009
    • Figure 48: Drivers of degree of rivalry in the OTC pharmaceuticals market in Mexico, 2009
    • Figure 49: Bayer AG: revenues & profitability
    • Figure 50: Bayer AG: assets & liabilities
    • Figure 51: Johnson & Johnson: revenues & profitability
    • Figure 52: Johnson & Johnson: assets & liabilities
    • Figure 53: Boehringer Ingelheim GmbH: revenues & profitability
    • Figure 54: Boehringer Ingelheim GmbH: assets & liabilities
    • Figure 55: Mexico OTC pharmaceuticals market distribution: % share, by value, 2009
    • Figure 56: Mexico OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Figure 57: Poland OTC pharmaceuticals market value: $ million, 2005-09
    • Figure 58: Poland OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 59: Poland OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Figure 60: Poland OTC pharmaceuticals market share: % share, by value, 2009
    • Figure 61: Forces driving competition in the OTC pharmaceuticals market in Poland, 2009
    • Figure 62: Drivers of buyer power in the OTC pharmaceuticals market in Poland, 2009
    • Figure 63: Drivers of supplier power in the OTC pharmaceuticals market in Poland, 2009
    • Figure 64: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Poland, 2009
    • Figure 65: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Poland, 2009
    • Figure 66: Drivers of degree of rivalry in the OTC pharmaceuticals market in Poland, 2009
    • Figure 67: GlaxoSmithKline Plc: revenues & profitability
    • Figure 68: GlaxoSmithKline Plc: assets & liabilities
    • Figure 69: Poland OTC pharmaceuticals market distribution: % share, by value, 2009
    • Figure 70: Poland OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Figure 71: South Africa OTC pharmaceuticals market value: $ million, 2005-09
    • Figure 72: South Africa OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 73: South Africa OTC pharmaceuticals market share: % share, by value, 2009
    • Figure 74: Forces driving competition in the OTC pharmaceuticals market in South Africa, 2009
    • Figure 75: Drivers of buyer power in the OTC pharmaceuticals market in South Africa, 2009
    • Figure 76: Drivers of supplier power in the OTC pharmaceuticals market in South Africa, 2009
    • Figure 77: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in South Africa, 2009
    • Figure 78: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in South Africa, 2009
    • Figure 79: Drivers of degree of rivalry in the OTC pharmaceuticals market in South Africa, 2009
    • Figure 80: Johnson & Johnson: revenues & profitability
    • Figure 81: Johnson & Johnson: assets & liabilities
    • Figure 82: South Africa OTC pharmaceuticals market distribution: % share, by value, 2009
    • Figure 83: South Africa OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Figure 84: Taiwan OTC pharmaceuticals market value: $ million, 2005-09
    • Figure 85: Taiwan OTC pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 86: Taiwan OTC pharmaceuticals market segmentation II: % share, by value, 2009
    • Figure 87: Taiwan OTC pharmaceuticals market share: % share, by value, 2009
    • Figure 88: Forces driving competition in the OTC pharmaceuticals market in Taiwan, 2009
    • Figure 89: Drivers of buyer power in the OTC pharmaceuticals market in Taiwan, 2009
    • Figure 90: Drivers of supplier power in the OTC pharmaceuticals market in Taiwan, 2009
    • Figure 91: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Taiwan, 2009
    • Figure 92: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Taiwan, 2009
    • Figure 93: Drivers of degree of rivalry in the OTC pharmaceuticals market in Taiwan, 2009
    • Figure 94: China Chemical and Pharmaceutical Co., Ltd.: revenues & profitability
    • Figure 95: China Chemical and Pharmaceutical Co., Ltd.: assets & liabilities
    • Figure 96: Sinphar pharmaceuticals co ltd: revenues & profitability
    • Figure 97: Sinphar pharmaceuticals co ltd: assets & liabilities
    • Figure 98: Daiichi Sankyo, Ltd.: revenues & profitability
    • Figure 99: Daiichi Sankyo, Ltd.: assets & liabilities
    • Figure 100: Taiwan OTC pharmaceuticals market distribution: % share, by value, 2009
    • Figure 101: Taiwan OTC pharmaceuticals market value forecast: $ million, 2009-14
+44 20 8816 8548

Ask a question about OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide

Enter the characters you see in the picture below
Captcha